We conducted a study comparing the utilization of modern immunotherapy relative to targeted BRAF/MEK inhibitors/chemotherapy in stage III and IV melanoma cases and evaluated factors influencing the timing of immunotherapy administration. This evidence concerns the gene MAP2K7 and melanoma.